Literature DB >> 1005563

The coincidence of schizophrenia and Parkinsonism: some neurochemical implications.

T J Crow, E C Johnstone, H A McClelleand.   

Abstract

The hypothesis has recently been advanced that increased activity of central dopaminergic mechanisms underlies the symptomatology of the schizophrenias. The evidence that dopaminergic transmission in the corpus striatum is impaired in Parkinson's disease suggests that observations on the relationship between Parkinson's disease and schizophrenia may illuminate the patholophysiology of the latter disease. Four cases are reported in which an illness with schizophrenic features developed in the setting of longstanding Parkinson's disease; attention is drawn to earlier reports of schizophrenic illnesses occurring as postencephalitic sequelae in the presence of a parkinsonian syndrome. These observations appear to conflict with the view that increased dopamine release in the striatum is necessary for the expression of schizophrenic psychopathology, but do not exclude the possibility that increased transmission may occur at other dopaminergic sites in the brain, for example the nucleus accumbens, tuberculum olfactorium or cerebral cortex. Similarly the dopamine receptor blockade hypothesis of the therapeutic effects of neuroleptic drugs cannot be maintained with respect to an action in the striatum in view of the differences between the actions of thioridazine and chlorpromazine in this structure, but may be tenable for actions at extra-straital sites.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1005563     DOI: 10.1017/s0033291700013763

Source DB:  PubMed          Journal:  Psychol Med        ISSN: 0033-2917            Impact factor:   7.723


  3 in total

1.  The role of dopamine in the antipsychotic effect and the pathogenesis of schizophrenia.

Authors:  T J Crow; E C Johnstone; A Longden; F Owen; G Riley
Journal:  Proc R Soc Med       Date:  1977

2.  RIT2 Polymorphisms: Is There a Differential Association?

Authors:  Babak Emamalizadeh; Javad Jamshidi; Abolfazl Movafagh; Mina Ohadi; Mahmoud Shekari Khaniani; Somayyeh Kazeminasab; Akbar Biglarian; Shaghayegh Taghavi; Marzieh Motallebi; Atena Fazeli; Azadeh Ahmadifard; Gholam-Ali Shahidi; Peyman Petramfar; Neda Shahmohammadibeni; Tahereh Dadkhah; Ehteram Khademi; Abbas Tafakhori; Ali Khaligh; Tannaz Safaralizadeh; Ali Kowsari; Arash Mirabzadeh; Amir Ehtesham Shafiei Zarneh; Mehdi Khorrami; Parasto Shokraeian; Mohammad Javad Soltani Banavandi; Behnam Safarpour Lima; Monavvar Andarva; Elham Alehabib; Minoo Atakhorrami; Hossein Darvish
Journal:  Mol Neurobiol       Date:  2016-03-03       Impact factor: 5.590

Review 3.  Psychosis in Parkinson's disease and parkinsonism in antipsychotic-naive schizophrenia spectrum psychosis: clinical, nosological and pathobiological challenges.

Authors:  John L Waddington
Journal:  Acta Pharmacol Sin       Date:  2020-03-05       Impact factor: 6.150

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.